1. Home
  2. SAR vs EBS Comparison

SAR vs EBS Comparison

Compare SAR & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Saratoga Investment Corp New

SAR

Saratoga Investment Corp New

HOLD

Current Price

$22.62

Market Cap

372.7M

Sector

Finance

ML Signal

HOLD

Logo Emergent Biosolutions Inc.

EBS

Emergent Biosolutions Inc.

HOLD

Current Price

$8.00

Market Cap

411.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAR
EBS
Founded
2007
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
372.7M
411.1M
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
SAR
EBS
Price
$22.62
$8.00
Analyst Decision
Hold
Strong Buy
Analyst Count
4
1
Target Price
$23.75
$12.00
AVG Volume (30 Days)
110.3K
638.8K
Earning Date
05-05-2026
04-30-2026
Dividend Yield
14.43%
N/A
EPS Growth
N/A
125.83
EPS
N/A
0.93
Revenue
N/A
$742,900,000.00
Revenue This Year
N/A
$1.29
Revenue Next Year
$0.39
N/A
P/E Ratio
$9.44
$8.66
Revenue Growth
N/A
N/A
52 Week Low
$20.78
$4.71
52 Week High
$25.64
$14.06

Technical Indicators

Market Signals
Indicator
SAR
EBS
Relative Strength Index (RSI) 50.59 43.26
Support Level $22.56 $7.73
Resistance Level $22.82 $8.54
Average True Range (ATR) 0.49 0.34
MACD 0.05 0.02
Stochastic Oscillator 48.24 21.09

Price Performance

Historical Comparison
SAR
EBS

About SAR Saratoga Investment Corp New

Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.

About EBS Emergent Biosolutions Inc.

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.

Share on Social Networks: